Insider Selling: CytomX Therapeutics (NASDAQ:CTMX) SVP Sells $202,178.64 in Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Marcia Belvin sold 31,492 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total transaction of $202,178.64. Following the transaction, the senior vice president directly owned 300,760 shares of the company’s stock, valued at $1,930,879.20. The trade was a 9.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

CytomX Therapeutics Trading Down 6.9%

Shares of CTMX stock opened at $4.45 on Friday. CytomX Therapeutics, Inc. has a 12-month low of $0.40 and a 12-month high of $8.21. The firm’s 50 day moving average is $5.28 and its 200 day moving average is $4.13. The stock has a market capitalization of $757.35 million, a P/E ratio of -111.25 and a beta of 2.44.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The company had revenue of $0.66 million for the quarter, compared to analysts’ expectations of $7.33 million. CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 19.77%. As a group, equities analysts predict that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current year.

Hedge Funds Weigh In On CytomX Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its position in CytomX Therapeutics by 83.2% during the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,000 shares in the last quarter. Farther Finance Advisors LLC bought a new stake in CytomX Therapeutics during the third quarter valued at about $25,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in CytomX Therapeutics in the fourth quarter worth about $35,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of CytomX Therapeutics in the third quarter worth about $34,000. Finally, May Hill Capital LLC bought a new position in shares of CytomX Therapeutics in the fourth quarter worth about $46,000. 67.77% of the stock is owned by institutional investors.

More CytomX Therapeutics News

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Multiple high‑profile analyst upgrades and big price‑target increases (Jefferies, Barclays, Guggenheim, Wedbush and others) have pushed positive momentum and attracted buyers. Jefferies raises price target to $16
• Positive Sentiment: Trading volume spiked after the analyst upgrade cycle, suggesting the upgrades translated into real buying interest rather than just headlines. Strong trading volume after upgrades
• Neutral Sentiment: CytomX priced an equity offering to raise about $234 million, which materially extends runway and funding for the pipeline but will dilute existing shareholders. Timing and use of proceeds will determine the net effect. Equity offering announcement
• Neutral Sentiment: Short‑interest reports in recent filings show effectively zero reported short interest (data appears inconsistent/NaN), so short positioning is not clearly driving moves at this time. Short interest data (reporting)
• Negative Sentiment: CytomX missed Q1/quarterly estimates on both EPS and revenue, a concrete near‑term negative that increases uncertainty around execution and near‑term cash generation. Shares down on disappointing earnings
• Negative Sentiment: An analyst cut the Q1 EPS forecast, adding to concerns about near‑term financial performance and guidance. Q1 EPS forecast decreased
• Negative Sentiment: Clustered insider selling on March 17 (CEO Sean McCarthy, CFO Christopher Ogden, SVP Marcia Belvin and others) — sizable block sales by multiple senior executives — is dampening sentiment even if some sales are routine. Insider sales report
• Negative Sentiment: Some sell‑side and independent commentary warn that early clinical data may not yet justify elevated valuations, which could pressure momentum traders and cap further upside until clearer clinical/corporate catalysts arrive. Valuation caution commentary

Wall Street Analyst Weigh In

A number of analysts recently commented on CTMX shares. Piper Sandler upped their price objective on CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Jefferies Financial Group raised their target price on CytomX Therapeutics from $8.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday. Barclays boosted their price target on CytomX Therapeutics from $10.00 to $16.00 and gave the company an “overweight” rating in a research note on Thursday. Guggenheim increased their price objective on shares of CytomX Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Oppenheimer reissued an “outperform” rating and issued a $12.00 price objective on shares of CytomX Therapeutics in a report on Monday, March 16th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, CytomX Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $13.22.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.